Abstract: Objective    To explore the protective effects of ginkgolide B (GB) on model rats with Parkinson's disease (PD).     Methods     PD rat models were established by intracerebral injection of 6-OHDA, and they were randomly divided into a sham group, a model group, a Madopar group (20 mg/kg) and low-, middle- and high-dose GB groups (15, 30, 60 mg/kg). The rats were randomly divided into a Sham group, a Model group, a GB 60 mg/kg group, a LY294002 group and a GB 60 mg/kg+ LY294002 group, and rotating experiment was used to detect the behaviors of rats. Kit test was used to detect the levels of MDA, SOD and GSH, and ELISA was applied to measure the levels of IL-6, IL-1β and TNF-α. Western blot was applied to detect the expressions of PI3K/Akt signaling pathway proteins in rat substantia nigra and striatal tissue.    Results     After treatment, the number of rotations of rats in Madopar group and middle- and high-dose GB groups was significantly less than that in model group (P<0.05). The levels of MDA, IL-6, IL-1β and TNF-α were significantly lower than those in model group (P<0.05), while the levels of SOD, GSH and protein expressions of p-PI3K, p-Akt were significantly higher than those in model group (P<0.05). Compared with the LY294002 group, the protein expressions of p-PI3K and p-Akt significantly increased (P<0.05), and the levels of MDA and IL-6, IL-1β and TNF-α significantly reduced (P<0.05) while the levels of SOD and GSH significantly increased (P<0.05) in the GB 60 mg/kg+ LY294002 group.   Conclusions    High-dose GB can improve the behaviors of PD rats, enhance the ability of anti-oxidative stress, relieve inflammatory injury, and play a certain protective effect. In addition, its role mechanism may be related to the regulation of PI3K/Akt signaling pathway.

Key words: Ginkgolide B,  ,  , Parkinson's disease,  , Neurological function,  , PI3K/Akt signaling pathway